Glenmark Pharmaceuticals Ltd has announced that it is all set to begin final stage global clinical trials for its experimental new molecule Melogliptin by the end of the year. The latter is a new treatment for diabetes.
Glenmark said the drug had successfully completed phase IIb, or mid-stage, clinical trials. The results showed that it was able to improve glycemic control and also had a neutral effect on body weight. The 12-week trial involved 494 patients and all of them had reduced instances of low blood sugar level.
The company added in a statement that it is still looking to outlicense the molecule.